Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Patrick, Burnett"'
Autor:
Meredith Tyree Polaskey, Heather Woolery-Llloyd, David Osborne, Patrick Burnett, Diane Hanna, Raj Chovatiya
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1071-1077 (2024)
Abstract Seborrheic dermatitis (SD) impacts a diverse demographic, with treatment effectiveness and suitability varying across hair types and cultural practices. Available shampoo treatments contain surfactants that compromise hair moisture and integ
Externí odkaz:
https://doaj.org/article/b76ee326f58a4ce7b582e3f812bdc635
Autor:
Zoe D Draelos, David N Adam, H Chih-ho Hong, Mark G Lebwohl, Charles W Lynde, Walter K Nahm, Kim A Papp, David M Pariser, Linda Stein Gold, Daniel Stewart, Robert C Higham, David R Berk, David Krupa, Patrick Burnett
Publikováno v:
British Journal of Dermatology. 188:810-812
This post hoc analysis evaluated efficacy and safety of roflumilast cream in patients with psoriasis involving the face/neck or intertriginous areas from a phase IIb trial. Of 331 patients enrolled in the phase IIb trial, 160 had psoriasis involving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31b6566569b004a78c9b5ea14a9890b8
https://doi.org/10.1093/bjd/ljad060
https://doi.org/10.1093/bjd/ljad060
Autor:
Matthew J. Zirwas, Zoe D. Draelos, Janet DuBois, Leon H. Kircik, Angela Y. Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence J. Green, Scott T. Guenthner, Laura K. Ferris, Seth B. Forman, Steven E. Kempers, Edward Lain, Charles W. Lynde, David M. Pariser, Darryl P. Toth, Paul S. Yamauchi, Robert C. Higham, David Krupa, Patrick Burnett, David R. Berk
Publikováno v:
JAMA Dermatology.
ImportanceCurrent topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety.ObjectiveTo assess safety and efficacy of roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis affecting the scalp, face, and/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca1dec1f89c02bd2aeda1f7193cbee56
https://doi.org/10.1001/jamadermatol.2023.0846
https://doi.org/10.1001/jamadermatol.2023.0846
Autor:
Christine Bangert, Christian Loesche, Hans Skvara, Regina Fölster-Holst, Jean-Philippe Lacour, Julie Jones, Patrick Burnett, Natalija Novak, Georg Stingl
Publikováno v:
Journal of Investigative Dermatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6cc306e008f810866e85bd5e8461091
https://doi.org/10.1016/j.jid.2023.01.040
https://doi.org/10.1016/j.jid.2023.01.040
Autor:
Melissa Olivadoti, Pearl Kwong, Wendy McFalda, Jayson M. Rieger, Scott Guenthner, David K. Glover, Kimberly Eads, Cynthia Willson, Morgan McCafferty, Patrick Burnett
Publikováno v:
Dermatology and Therapy
Introduction Verrucae vulgaris, or common warts, is a common skin condition for which there is no US Food and Drug Administration-approved treatment. Compounded cantharidin has been used to treat warts for years but lacks a controlled formulation, co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b28dfcb12d5af17e0b807fa65745166a
https://doi.org/10.1007/s13555-021-00576-y
https://doi.org/10.1007/s13555-021-00576-y
Autor:
Mark Lebwohl, Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, David Adam, H. Chih-ho Hong, Leon Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham, David Krupa, David Berk
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s111
Background: Roflumilast cream is a potent phosphodiesterase 4 inhibitor recently approved in the United States for treatment of plaque psoriasis with no limitations on duration of use. An open-label trial was conducted to evaluate long-term safety (5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc4f922742ab3127a08f61170ad2fea4
https://doi.org/10.25251/skin.7.supp.111
https://doi.org/10.25251/skin.7.supp.111
Autor:
Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Scott Guenthner, Adelaide Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David Berk, David Chu
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s196
Introduction: Seborrheic dermatitis (SD) is a common, chronic, inflammatory dermatosis that affects patients of all ages with a global prevalence ≥5%. Treatments usually consist of topical therapies, including antifungals and low potency corticoste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f22b52dbe2ec81b5a5d395fe1eb1476f
https://doi.org/10.25251/skin.7.supp.196
https://doi.org/10.25251/skin.7.supp.196
Autor:
Davidson Matthew Gene, Sahra Niazi, Luke Anschutz, Cynthia Willson, Bradford Brabec, Patrick Burnett
Publikováno v:
Journal of Drugs in Dermatology. 20:70-75
Background This Phase 2, open-label study evaluated the safety, efficacy, systemic exposure, and impact on quality of life (QoL) with treatment using VP-102, a drug-device combination containing cantharidin (0.7% w/v) in subjects with molluscum conta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f7c5d4412093d0e963313f4fec1141
https://doi.org/10.36849/jdd.5626
https://doi.org/10.36849/jdd.5626
Autor:
Laura K Ferris, April W Armstrong, James Del Rosso, Zoe D Draelos, Melinda Gooderham, Mark Lebwohl, Kim A Papp, Jennifer Soung, Linda Stein Gold, David Krupa, Robert C Higham, Patrick Burnett, David R Berk
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 6:s57
N/A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ad773711b7679cb7e5e931d853c9b1d
https://doi.org/10.25251/skin.6.supp.57
https://doi.org/10.25251/skin.6.supp.57
Autor:
Mark G, Lebwohl, Leon H, Kircik, Angela Y, Moore, Linda, Stein Gold, Zoe D, Draelos, Melinda J, Gooderham, Kim A, Papp, Jerry, Bagel, Neal, Bhatia, James Q, Del Rosso, Laura K, Ferris, Lawrence J, Green, Adelaide A, Hebert, Terry, Jones, Steven E, Kempers, David M, Pariser, Paul S, Yamauchi, Matthew, Zirwas, Lorne, Albrecht, Alim R, Devani, Mark, Lomaga, Amy, Feng, Scott, Snyder, Patrick, Burnett, Robert C, Higham, David R, Berk
Publikováno v:
JAMA. 328:1073
ImportanceOnce-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in a phase 2b trial of patients with psoriasis.ObjectiveTo evaluate the efficacy of roflumilast cream, 0.3%, applied on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::565d537d0b59fe6b651c8d0f333ec1af
https://doi.org/10.1001/jama.2022.15632
https://doi.org/10.1001/jama.2022.15632